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Abstract
Background: The current tuberculosis vaccine is a live vaccine derived from Mycobacterium bovis
and attenuated by serial in vitro passaging. All vaccine substrains in use stem from one source, strain
Bacille Calmette-Guérin. However, they differ in regions of genomic deletions, antigen expression
levels, immunogenicity, and protective efficacy.
Results: As a RecA phenotype increases genetic stability and may contribute restricting the
ongoing evolution of the various BCG substrains while maintaining their protective efficacy, we
aimed to inactivate recA  by allelic replacement in BCG vaccine strains representing different
phylogenetic lineages (Pasteur, Frappier, Denmark, Russia). Homologous gene replacement was
achieved successfully in three out of four strains. However, only illegitimate recombination was
observed in BCG substrain Russia. Sequence analyses of recA revealed that a single nucleotide
insertion in the 5' part of recA led to a translational frameshift with an early stop codon making BCG
Russia a natural recA mutant. At the protein level BCG Russia failed to express RecA.
Conclusion: According to phylogenetic analyses BCG Russia is an ancient vaccine strain most
closely related to the parental M. bovis. We hypothesize that recA inactivation in BCG Russia
occurred early and is in part responsible for its high degree of genomic stability, resulting in a
substrain that has less genetic alterations than other vaccine substrains with respect to M. bovis
AF2122/97 wild-type.
Background
Tuberculosis is an infectious disease of enormous global
importance. It is estimated that about one third of the
human population is latently infected with Mycobacterium
tuberculosis with 1.6 million people dying annually from
the disease [1]. The currently employed tuberculosis vac-
cine, Mycobacterium bovis Bacille Calmette-Guérin (BCG)
was originally derived from a virulent strain of M. bovis
back to 1921, by repeated passages on potato slices
soaked in glycerol-ox byle. The primary attenuation is
attributed to loss of RD1 locus, which affects a protein
secretion pathway [2-5]. Subsequent propagation of BCG
in several laboratories around the world resulted in fur-
ther  in vitro evolution, which is still ongoing. Genetic
alterations are mainly due to deletions and duplications
[6], although single nucleotide polymorphisms (e.g. in
mmaA3 and sigK) have also been described [7,8]. The var-
ious genetic alterations – some presumably involving
RecA-mediated recombination – affect the antigenic, pro-
tective, and metabolic properties of BCG. Thus, the term
Published: 17 July 2008
BMC Microbiology 2008, 8:120 doi:10.1186/1471-2180-8-120
Received: 26 May 2008
Accepted: 17 July 2008
This article is available from: http://www.biomedcentral.com/1471-2180/8/120
© 2008 Keller et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Microbiology 2008, 8:120 http://www.biomedcentral.com/1471-2180/8/120
Page 2 of 9
(page number not for citation purposes)
BCG does not refer to an entity but comprises a set of dif-
ferent substrains. Since the early sixties, freeze dried and
lyophilized secondary seed lots are used as source of com-
mercially available vaccine strains. WHO vaccine produc-
tion guidelines [9] call for fresh cultures from secondary
seed lots and propose not to exceed twelve passages from
the primary seed lot. These recommendations have been
modified recently, suggesting not to exceed four passages
as phenotypic alterations were observed in vaccine
batches undergoing as little as twelve subcultivations [10].
Results
Generation of recA knock-out strains
To establish BCG as a vector for stable heterologous anti-
gen expression we intended to stabilize the genome of
four BCG substrains representing different phylogenetic
lineages by deletion of recA. A recA phenotype is desirable
for live mycobacterial vaccines as homologous recombi-
nation is an important contributor of genomic evolution
[11,12]. We constructed a replacement vector (Additional
file 1) carrying an unmarked, inactive deletion of the recA
allele. In this vector, a hygromycin resistance cassette and
the counterselectable marker sacB  were cloned down-
stream of the recA allele. Transformation of this kind of
vector allows generation of allelic replacement mutants by
two subsequent selection steps. In a first step, transform-
ants that have integrated the knock-out plasmid into the
bacterial chromosome are selected on hygromycin B con-
taining media. Integration of the vector by homologous
recombination, i. e. 3' or 5' of the genomic recA, is
revealed by Southern blot analyses. In a second step,
sucrose-selection is used to select for mutants that have
undergone a second intramolecular recombination result-
ing either in inactivation of the recA gene or in reversion
to wild-type.
Most of the transformants obtained in substrains Pasteur,
Frappier, and Denmark resulted from homologous inte-
gration of the targeting vector (3'or 5') at the recA locus
(Table 1 and Figure 1A). Subsequent counter-selection of
clones arising from homologous recombination events
readily resulted in recA deletion mutants as demonstrated
by Southern blot analyses. In striking contrast, all trans-
formants (16/16 analyzed) of substrain Russia resulted
from illegitimate recombination (Table 1 and Figure 1B).
Southern blot analysis shows a virtually at random inte-
gration of the suicide knock-out plasmid containing the
inactivated recA in substrain Russia. The presence of a 1.9-
kb fragment corresponding to the original recA and the
presence of a second fragment of varying size indicates
non-homologous illegitimate recombination.
Genomic recA sequence
The absence of marker integration by homologous recom-
bination prompted us to examine the genomic recA
sequence in BCG Russia in comparison to the annotated
sequence of BCG Pasteur 1173P2 [6]. We found a single
insertional mutation 413 bp from the recA start (Figure 2),
which leads to a translational frameshift and a premature
stop codon at amino acid position 140 in the major cen-
tral RecA domain (residues 31–269). The truncated RecA
has a length of 139 instead of 790 amino acids and lacks
the complete C-terminal part of the protein including
loops L1 (residues 156–165) and L2 (195–210) impli-
cated in DNA binding [13]. BCG Frappier, Denmark, and
Pasteur recA were identical with the annotated reference
sequence encoding a functional RecA.
RecA expression at the protein level
Bacteria respond to DNA-damage by coordinated expres-
sion of a multitude of genes involved in repair and control
of cell division – the SOS response [14]. The SOS response
was induced by addition of the DNA-damaging agent
mitomycin C (0.2 μg mL-1) to a BCG culture, followed by
incubation for an additional 24 hours [15]. Western blot
analysis using a polyclonal mouse α-RecA antibody dem-
onstrated induction of RecA in strain BCG Pasteur, but
absence and failure of induction of RecA in BCG Russia
(Figure 3). A genetically engineered BCG Pasteur recA
mutant (this study) was used as a negative control.
Table 1: Analysis of recombinants.
BCG substrain no. of HygR colonies no. of analyzed HygR transformants spontaneously HygR
homologous recombinants illegitimate recombinants
recA+ substrains
Pasteur 54 11 2 3 6
Frappier 90 9 2 1 6
Denmark 377 21 10 2 9
Σ recA+ 521 41 14 6 21
recA- substrain
Russia 72 23 0 16 7
Analysis of recombinants in BCG substrains Pasteur, Frappier, Denmark, and Russia following transformation with recA targeting plasmid pGEM7-
recA::3xstop-hsp60-sacB-hyg-aphBMC Microbiology 2008, 8:120 http://www.biomedcentral.com/1471-2180/8/120
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Discussion
Replication errors, transpositions and recombination
events contribute to genetic alterations and drive genome
evolution. For BCG various differences in morphology,
growth rate, protein expression and genetic make-up have
been noted among commercially available substrains
Southern blot analysis of the recA locus Figure 1
Southern blot analysis of the recA locus. (A) BCG Frappier. Lane 1, parental M. bovis BCG Frappier; lane 2, single-crosso-
ver transformant obtained with plasmid pGEM7-recA::3xstop-hsp60-sacB-hyg-aph; lanes 3-4, recA (unmarked) knock-out 
mutants obtained after counterselection of a single-crossover transformant. (B) BCG Russia. Lanes 1–9 transformants obtained 
with plasmid pGEM7-recA::3xstop-hsp60-sacB-hyg-aph resulting from illegitimate recombination; lane 10, parental strain. (C) 
Schematic drawing of the BCG recA locus: the wild-type locus is shown along with the vector used for inactivation, 5' and 3' sin-
gle-crossover transformant, knock-out mutant.
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[16]. This is presumably a result of the numerous serial
passages on natural (potato slices trenched in ox bile) and
artificial media, which have led to the acquisition of
genomic alterations and further attenuation. Of note,
meta-analyses of BCG vaccination trials have indicated
protective efficacies ranging from 0–80%. A correlation
between the number of serial in vitro passages and the
decrease in protective efficacy has been observed [17].
Several reasons have been put forward to explain the var-
ying protective efficacies of BCG, among others genetic
differences between vaccine substrains as well as within
an individual substrain [18]. More recently it has been
suggested that the protective efficacy of ancient vaccine
strains charcterized by few regions of difference (Figure 4)
may be superior to that of the later ones that are more
widely used [6]. We have added the newly identified sin-
gle nucleotide polymorphism to an existent phylogenetic
tree. It will be of interest to see whether recA is functional
in other ancient strains (e.g. BCG Moreau or Japan).
Sequencing of recA may also help to clarifiy the uncertain
origin of the two subcultures of BCG Japan [6].
The RecA-family recombinases have a central role in DNA
repair, restoration of stalled replication forks, induction of
SOS response, mutagenesis and homologous recombina-
tion [19]. In E. coli, RecA is involved in several homolo-
gous recombination pathways, where it promotes the
central steps, i.e. aligning and pairing two DNA mole-
cules, and then promoting a strand switch followed by
branch migration [19]. RecA is both ubiquitous and
highly conserved among a range of organisms, but varia-
tions of the prototypic E. coli paradigm exist. recA of path-
ogenic mycobacteria (M. tuberculosis complex, M. leprae)
but not of non-pathogenic mycobacteria (e.g. M. smegma-
tis) is interrupted by an in-frame open reading frame
encoding an intein [20]. RecA intein is removed from the
precursor RecA by an autocatalytic protein splicing reac-
tion and active RecA, which can complement a M. smeg-
matis recA mutant [21,22] is generated by ligation of
amino- and carboxy terminal fragments mediated by
intein.  M. tuberculosis RecA activity differs from E. coli
RecA activity with respect to single strand DNA-dependent
ATP-hydrolysis, co-factor requirement and pH-optimum
[23]. Homologous recombination in M. tuberculosis com-
plex is sometimes masked by a high degree of illegitimate
recombination in certain experiments [24]. The high
degree of illegitimate recombination has been attributed
to the unusual structure of recA [25]. Alternatively, the
high degree of illegitimate recombination may be due to
the absence of a mismatch repair system [26], which has
anti-recombination activity [27]. However, homologous
recombination essentially depends on recA  as demon-
Comparative alignment Figure 2
Comparative alignment. Comparative alignment of DNA sequencing electropherograms for M. bovis BCG Pasteur 1173P2 
and BCG Russia displaying the insertional SNP (C414) in the recA gene of BCG Russia. As a consequence Leu139 is changed to 
Ala, which is immediately followed by a premature stop codon (D140*). Nucleotide and amino acid numbering starts at the 
recA initiation codon.
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strated in a gene conversion assay in a M. bovis BCG recA
mutant [28]. Of note a homologue of E. coli RecT, a pro-
tein functionally overlapping RecA, is missing in M. tuber-
culosis [29]. Likewise, other recombination genes are also
absent from the M. tuberculosis genome (e.g. recE, recJ)
[26].
Comparative genomics indicate that recombination
events are a major driving force of bacterial evolution
[12]. There is extensive evidence for large-scale rearrange-
ments, duplications and deletions resulting from homol-
ogous recombination in M. leprae [30], M. tuberculosis [31]
and M. bovis BCG [6]. Half of the proteins present in the
tubercle bacillus originate from gene duplications [32].
Tandem duplications are generally caused by unequal
crossover between homologous sequences or by recombi-
nation of short DNA homologies. Homologous recombi-
nation between similar sequences may invert or delete
genes. Several deletions in the M. tuberculosis H37Rv
genome resulted from recombination between adjacent
repeats of IS6110 elements [31,33]. Sometimes, the
molecular mechanisms underlying alterations at particu-
lar loci remain obscure and subsequent alterations may
mask initial events, e.g. tandem duplication of the DU2
region in M. bovis BCG Pasteur arose from duplication of
a 100 kb genomic segment that subsequently incurred an
internal deletion of 64 kb [18].
Conclusion
Comparative genome and transcriptome analyses indicate
that BCG Russia is an ancient BCG strain most closely
related to the original strain attenuated by Calmette and
Guérin [6]. However, a key piece of the puzzle was miss-
ing. What was the molecular mechanism underlying the
high degree of genome conservation in BCG Russia? Here,
analysis of the recA locus provides a possible clue. RecA,
which is the key element of homologous recombination
and a driving force in mycobacterial genome evolution
but which is not mandatory for conferring protection of
BCG in animal models of tuberculosis [11], is disrupted
by single nucleotide insertion in BCG Russia. This muta-
tion results in a frameshift and premature translational
stop and most probably contributed to the genome stabil-
ity of this substrain of BCG. Of note genome stability of
Western blot analysis Figure 3
Western blot analysis. Western blot analysis of cell-free protein extracts from different BCG preparations (with and with-
out SOS response induction by mitomycin C). Mature RecA protein has an approximate molecular weight of 38 kDa. KatG (81 
kDa) served as a loading control. Bands migrating around 50 kDa are unspecific.
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the obligate endosymbionts of aphids, Buchnera aphidi-
cola, is also associated with lack of recA [12].
Methods
Bacterial strains
Escherichia coli DH5α was obtained from Pharmacia (GE
Healthcare, Uppsala, Sweden) and was used for plasmid
propagation. M. bovis BCG Pasteur 1173P2 was obtained
from the strain collection of the Institute Pasteur, Paris,
France (strain #CIP105050). M. bovis BCG Denmark
(1331) was obtained in the form of a vaccine production
lot through the Statens Serum Institute, Copenhagen,
Denmark.  M. bovis BCG Frappier (Montreal, ATCC
#35735) primary lot, dated 1973, lot number 1376141,
was obtained from the American Type Culture Collection
(ATCC), Rockville, MD, USA. The Frappier strain held by
ATCC was initially transferred from the Institut Pasteur to
Frappier's Institute in Montreal in 1937, was integrated in
the Trudeau Mycobacterial Culture Collection and finally
went to the ATCC. A vaccine production lot 547–1104 K.
1491 of M.bovis  BCG Russia (corresponding to ATCC
#35740) was obtained through Medgamal Inc. (TD Aller-
gen, Moscow, Russia). This was the first documented
daughter strain distributed by Institut Pasteur in 1924
[34] going directly to Russia. It is referred as an 'early
strain' with regards to its genetic characteristics (regions of
difference, insertional elements, antigen expression pat-
tern).
Genealogy of BCG vaccine substrains Figure 4
Genealogy of BCG vaccine substrains. Genealogy of BCG vaccine substrains, modified from [6] with permission, copy-
right (2007) National Academy of Sciences, U.S.A., displaying the original virulent ancestor strain Mycobacterium bovis (isolated 
by Nocard in 1908) and the subsequent series of genomic alteration including deletions of regions of difference (RD), single 
nucleotide polymorphisms, and duplications of genomic regions. The recA alteration (recA_D140*), the mmaA3 point mutation 
[8], and the 22-bp deletion in Rv3405c in BCG Japan [39] have been added to the scheme.
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The identity of the BCG substrains was confirmed using
morphological features (roughling, generation time), PCR
amplification and sequencing of described regions of dif-
ference as described by [35].
Media, transformation and DNA damage induction. The
media for growing E. coli DH5α, and substrains of Myco-
bacterium bovis BCG have been described previously [22].
M. bovis BCG substrains were revitalised by addition of 1
mL Middlebrook 7H9 medium to a lyophilized batch. For
DNA damage induction experiments M. bovis BCG was
grown in Middlebrook 7H9 medium with addition of
10% (vol/vol) OADC in motionless tissue culture flasks in
a 37°C incubator. Published protocols were followed for
the preparation of electrocompetent cells of mycobacteria
and for electroporation [22]. The recA mutants of BCG
Pasteur, Denmark and Frappier were generated by allelic
replacement using a suicide knock-out vector.
To induce DNA damage, mitomycin C (0.2 μg ml-1) was
added to 20 mL of growing cultures (at an OD600 of 0.6)
and incubated for 24 h. Thereafter, bacteria were har-
vested by centrifugation and prepared for cell lysis.
Construction of recA knock-out plasmid
Suicide vector pGEM7-recA::3xstop-hyg-aph was generated
as follows. A 5.2-kb ApaI fragment from plasmid pEJ126
[36] containing the M. tuberculosis recA gene was sub-
cloned into the PstI site of plasmid pBluescript-KSII(-)
after blunting of both fragments with T4 DNA polymer-
ase, resulting in plasmid pBluescript-recA. From this vec-
tor a 1.3-kb internal PstI fragment (recA bps 504–1758,
corresponding to protein residues 169–586) was replaced
by a 22-mer triple translation stop insert with an internal
MunI restriction site and PstI overhanging ends (Addi-
tional file 1). This 22-mer was generated by annealing of
dimeric oligonucleotide primers with 5'-phosphorylated
ends. Briefly, two complementary 5'-phosphorylated oli-
gonucleotides (Microsynth, Belgach, Switzerland) were
mixed in annealing buffer (10 mM Tris-HCl, pH 8.0; 50
mM NaCl; 1 mM EDTA) at equal volumes (resulting in a
final concentration of 5 μM per oligonucleotide). The
mixture was heated to 96°C for 5 minutes and cooled
down to 25°C over a period of 8 hours. The annealing
product was diluted 1:10 and used for ligation to result in
plasmid pBluescript-recA::3xstop.
An hsp60-sacB construct in form of an EcoRV/BamHI frag-
ment from plasmid pLO2 [37] was ligated to the BamHI/
EcoRI site of pMV361 [38] to result in pMV361-hsp60-
sacB, wherefrom an XbaI/XhoI fragment was ligated in the
XbaI/SacI site of pBluescript-IIKS(-) (Strategene, La Jolla,
CA, USA), to result in pBluescript-IIKS-hsp60-sacB. The
later plasmid was digested with ApaI and NheI and a 2514-
bp fragment ligated into pGEM7-Zf(+) (Promega, Madi-
son, WI, USA) digested with XbaI and ApaI, thereby excis-
ing 17 bps from the multiple cloning site to result in
pGEM7-hsp60-sacB (5494 bps), expressing sacB under the
control of the mycobacterial hsp60 promoter. A 1.3-kbp
aph  cassette isolated as a PstI fragment from plasmid
pUC4K (Pharmacia) was ligated into the NsiI restriction
site of pGEM7-hsp60-sacB to result in pGEM7-hsp60-sacB-
aph. Then we introduced a 1.3-kb hyg fragment (cut with
Bpu1102I and Van91I, treated with T4 DNA polymerase to
create blunt ends) encoding the hygromycin B resistance
cassette into pGEM7-hsp60-sacB-aph  (cut with SacI and
treated with T4 DNA polymerase). The resulting plasmid
pGEM7-hsp60-sacB-aph-hyg was cut with EcoRV and SpeI.
We subsequently introduced a 4-kb recA::3xstop fragment
from pBluescript-recA::3xstop (cut with EcoRV and SpeI),
the resulting suicide vector pGEM7-recA::3xstop-hsp60-
sacB-hyg-aph was used for transformation of BCG strains.
DNA isolation, sequencing and alignment
DNA was extracted from BCG colonies grown on 7H10.
The recA gene was amplified from genomic DNA (10 ng)
by Pfu DNA polymerase using primers #1 and #2. The
product was cleaned via gel purification and sequenced
using primers #1 to #9 (Additional file 2) using an ABI
PRISM 310 DNA sequencer (Applied Biosystems, Forster
City, CA, USA). The sequences were aligned using Laser-
gene (DNASTAR, Madison, WI, USA) SeqMan (version 6).
The aligned sequence was compared via BLAST software
to the recA sequence of M. bovis BCG substrain Pasteur
1173P2 [6]. Standard techniques were applied for South-
ern blot analysis. Approximately 500 ng of genomic DNA
was digested with SmaI and hybridized to a recA probe.
Preparation of cell-free extracts
Untreated and mitomycin-C-treated bacteria were har-
vested by centrifugation, washed with PBS buffer (pH 7.2)
and resuspended in 300 μL PBS containing 0.5% protease
inhibitor cocktail (Sigma). Bacteria were lysed in screw-
cap tubes in a water immersion (ice-chilled) sonicator
(Elma, Singen, Germany), using maximum duty-cycle
during 1 h 20 min with a cooling interval every 20 min.
The crude lysate was clarified by spinning at 1 000 × g dur-
ing 10 min.
Western blotting
Cell-free extracts corresponding to 50 μg total protein
(quantification via Bradford assay) were used for Western
blot analyses. Following SDS-PAGE in a 13.3% polyacry-
lamide gel, proteins were blotted to a PVDF membrane
using a semi-dry blotter (Biorad, Hercules, CA, USA) at
constant current (0.3 A) for 30 min. Equal loading of pro-
teins was confirmed by Coomassie staining, and by blot-
ting with antibodies against the constitutively expressed
mycobacterial protein KatG using a polyclonal mouse α-
KatG antibody (1:2500). Detection of RecA was carriedBMC Microbiology 2008, 8:120 http://www.biomedcentral.com/1471-2180/8/120
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out using a polyclonal mouse α-RecA antibody (1:1000).
Secondary antibody was HRP-conjugated goat α-mouse
antibody (1:2500).
Accession number
DNA sequence of M. bovis BCG substrain Russia recA has
been deposited with GenBank data base under accession
EU442641.
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